Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: A slow-titration regimen

International Journal of Clinical Practice

Volumn 60, Issue 5, 2006, Pages 533-540

  Thavichachart, Nantika ^a   Phanthumchinda, K ^a   Chankrachang, S ^b   Praditsuwan, R ^c   Nidhinandana, S ^d   Senanarong, V ^e   Poungvarin, N ^e  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHIANG MAI UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Efficacy; Galantamine; Tolerability

Indexed keywords

GALANTAMINE;

ABDOMINAL PAIN; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; BODY WEIGHT DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTERVIEW; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS; SYMPTOM; THAILAND; VOMITING; WEIGHT REDUCTION;

AGED; ALZHEIMER DISEASE; CEREBROVASCULAR DISORDERS; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALANTAMINE; HUMANS; MALE; NOOTROPIC AGENTS; TREATMENT OUTCOME;

EID: 33646261656     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00892.x     Document Type: Article

References (39)

1. Chung JA, Cummings JL. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: Characteristics and treatment. Neurol Clin 2000; 18: 829-46.
2. Gorelick PB. Risk factors for vascular dementia and Alzheimer disease. Stroke 2004; 35: 2620-2.
3. Luchsinger JA, Mayeux R. Cardiovascular risk factors and Alzheimer's disease. Curr Atheroscler Rep 2004; 6: 261-6.
4. Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: 106-14.
5. Skoog I. Vascular aspects in Alzheimer's disease. J Neural Transm Suppl 2000; 59: 37-43.
6. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju V. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomized trial. Lancet 2002; 359: 1283-90.
7. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci 2002; 977: 196-215.
8. Kalaria RN. Comparison between Alzheimer's disease and vascular dementia: Implications for treatment. Neurol Res 2003; 25: 661-4.
9. Kurz AF, Erkinjuntti T, Small GW, Lilienfeld S, Damaraju CR. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. Eur J Neurol 2003; 10: 633-40.
10. Woodruff-Pak DS, Vogel RW, Wenk GL. Galantamine effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 2001; 98: 2089-94.
11. Lilienfeld S, Parys W. Galantamine: Additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11: 19-27.
12. Kewitz H, Wilcock G, Davis B. Galantamine in Alzheimer's disease. In: Giacobini E, Becker R, eds. Alzheimer's Disease: Therapeutic Strategies. Boston, MA: Birkhauser, 1994.
13. Dal-Bianco P, Maly Wober J, Lind C et al. Galantamine treatment in Alzheimer's disease. J Neural Transm 1991; 33: 59-63.
14. Thomsen T, Bickel U, Fischer JP, Kewitz H. Galantamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1990; 1: 46-51.
15. Wilcock GK, Scott M, Pearsall T, Neubauer K, Boyle M, Razay G. Galantamine and the treatment of Alzheimer's disease. Int J Geriatr Psychiatry 1993; 8: 781.
16. Farlow MR, Evans RM. Pharmacological treatment of cognition in Alzheimer's dementia. Neurology 1998; 51: 36-44.
17. Blacker D, Albert MS, Bassett SS. Reliability and validity of NINDCS-ADRDA criteria for Alzheimer's Disease. The National Institute of Mental Health Geriatrics Initiative. Arch Neurol 1994; 51: 1198-204.
18. Roman GC, Tatemichi TC, Erkinjuntti T. Vascular dementia: Diagnostic criteria for research studies. Report of the NINDS- AIREN International Workshop. Neurology 1993; 43: 250-60.
19. Folstein M, Folstein S, McHugh P. Mini-mental state. A practical method for grading the cognitive status of patients for the clinician. J Psychiatric Res 1975; 12: 189-98.
20. Galasko D. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): 33-9.
21. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
22. Wilcock G, Howe I, Coles H et al.; Members of the GAL-GBR- 2 Study Group. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drug Aging 2003; 10: 777-89.
23. Rosler M, Anand R, Cicin-Sain A on behalf of the B303 Exelon Study Group. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial. BMJ 1999; 318: 633-8.
24. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT; the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-45.
25. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropharmacol 1998; 8: 67-75.
26. Raskind MA, Peskind ER, Wessel T, Yuan W; the Galantamine USA- 1 Study Group. Galantamine in AD: A 6 month randomized, placebo-controlled trial with a 6 month extension. Neurology 2000; 54: 2261-8.
27. Schrattenholz A, Pereira ER, Roth U, Weber K, Albuquerque EX, Maelick A. Agonist responses of neuronal acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol 1996; 49: 1-6.
28. Albuquerque EX, Alkondon M, Pereira ER. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997; 280: 1117-36.
29. Vasilenko ET, Tonkopii VD. Characteristics of galantamine as a reversible inhibitor of cholinesterase. Biokhimiia 1974; 39: 701-3.
30. Bores GM, Huger FP, Petko W. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galantamine. J Pharmacol Exp Ther 1996; 277: 728-38.
31. Levin ED, Simon BB. Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 1998; 138: 217-30.
32. Newhouse PA, Potter A, Levin ED. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997; 11: 206-28.
33. Giacobini E. Do cholinesterase inhibitors have disease modifying effects in Alzheimer's disease? CNS Drugs 2001; 1: 61-9.
34. Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-88.
35. Nordberg A. Nicotinic receptors abnormalities of Alzheimer's disease: therapeutic implication. Biol Psychiatry 2001; 49: 200-10.
36. Granon S, Passetti F, Thomas KL. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000; 20: 1208-15.
37. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001; 4: 1224-9.
38. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-95.
39. Imbimbo BP, Verdelli G, Martelli P, Marchesini D, the Eptastigmine Study Group. Two-year treatment of Alzheimer's disease with eptastigmine. Dement Geriatr Cogn Disord 1999; 10: 139-47.